文献速递肾癌与肾肿瘤

手术治疗肾细胞癌的长期复发风险:ECOG-ACRIN E2805试验队列的事后分析

Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort.
PubMed 文献 · Eur Urol · 2019-11-06

该研究对ECOG-ACRIN E2805试验队列中1943例手术治疗肾细胞癌患者进行事后分析,其中730例发生复发。术后0、12、24、36、48、60个月时的36个月累积复发率分别为31%、26%、19%、16%、19%、20%。术后0个月时年龄、病理T3/4期、病理N1/2期及Fuhrman 3/4级是独立复发预测因素,但术后60个月时未观察到这些因素。

要点

  • 术后60个月时36个月累积复发率仍达20%,支持中高危患者5年后继续影像监测。
  • 术后0个月时病理T3/4期(HR=1.56)和N1/2期(HR=2.38)为独立复发预测因素。
  • Fuhrman 3级(HR=1.36)和4级(HR=2.41)在术后0个月时与复发独立相关。

核心结论

  • 手术治疗的中高危局限性肾细胞癌患者术后5年以上复发率仍显著,应继续影像监测。

研究设计与样本

  • 对ECOG-ACRIN E2805试验队列进行事后分析,纳入1943例手术治疗患者,其中730例复发。
  • 采用条件生存模型动态评估术后设定间隔的36个月累积复发率。

主要发现

  • 术后0、12、24、36、48、60个月时的36个月累积复发率分别为31%、26%、19%、16%、19%、20%。
  • 术后0个月时年龄、病理T3/4期(HR=1.56)、病理N1/2期(HR=2.38)、Fuhrman 3级(HR=1.36)和4级(HR=2.41)为独立复发预测因素。
  • 术后60个月时上述因素未显示为独立预测因素。

关键数值与推荐

  • 术后0个月时病理T3/4期复发风险比HR=1.56。
  • 术后0个月时病理N1/2期复发风险比HR=2.38。
  • 术后0个月时Fuhrman 3级HR=1.36,4级HR=2.41。

临床怎么用

  • 对中高危局限性肾细胞癌术后患者,监测影像应持续至5年以上。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, surveillance guidelines following surgical resection of clinically localized renal cell carcinoma (RCC) are clear within the first 5 yr; however, these lack the same degree of objectivity following this cutoff. We sought to investigate the long-term risk of recurrence in surgically treated RCC in order to determine the utility of long-term surveillance. A post hoc analysis of patients within the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805 trial cohort was performed. The 36-mo cumulative incidence of recurrence was assessed at set intervals following surgery, in order to dynamically assess recurrence through the use of a conditional survival model. Of the 1943 patients included in the original cohort, 730 developed recurrence. The 36-mo cumulative incidences of recurrence were found to be 31%, 26%, 19%, 16%, 19%, and 20% for patients at 0, 12, 24, 36, 48, and 60 mo from surgery, respectively. At 0 mo from surgery, age, pathological T3/4 stage (hazard ratio [HR] = 1.56), pathological N1/2 stage (HR = 2.38), and Fuhrman grades 3 and 4 (HR = 1.36 and HR = 2.41, respectively) were independent predictors of recurrence; however, this was not seen at 60 mo following surgery. These findings support that surveillance imaging should be performed beyond 5 yr following surgical resection of intermediate- to high-risk RCC. PATIENT SUMMARY: : Follow-up for surgically resected localized renal cell carcinoma should be performed beyond 5 yr, for the rates of recurrence remain significant beyond this 5 yr endpoint.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Jamil ML, Keeley J, Sood A, et al. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort. Eur Urol. 2019. PMID: 31703971. doi:10.1016/j.eururo.2019.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。